Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported ...

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare “For more than 25 years, our clients have entrusted us to provide the ...

Simulations Plus, Inc. (NASDAQ:SLP) is one of the top 10 medical AI companies to buy according to analysts. On July 29, the company confirmed that its artificial intelligence-driven drug design ...

The drug development software and services provider reported adjusted earnings per share of $0.13 for the quarter ended November 30, 2025, missing the analyst estimate of $0.19 by $0.06. Revenue came ...

Detailed price information for Simulations Plus Inc (SLP-Q) from The Globe and Mail including charting and trades.

SUMMARY Simulations Plus(NASDAQ:SLP) reported mixed operational results for Q3 FY2025, as inorganic revenue gains from acquisitions were offset by organic decline and profitability was burdened by a ...

“We are honored to collaborate with ETC, a consortium representing leaders in pharmaceutical innovation who recognize the critical role GastroPlus already plays in drug development,” said Dr. Xavier ...

Simulations Plus (SLP) announced that it has entered a new funded collaboration with the Enabling Technologies Consortium ETC . This partnership is aimed at advancing in vitro-in vivo correlation or ...